Sweden’s Xbrane Lays Out Ranibizumab Ambitions

As Key Biosimilar Trial Affected By COVID-19

Eye
Xbrane is eyeing the considerable size of the anti-VEGF market for its biosimilar ranibizumab candidate • Source: Shutterstock

More from Biosimilars

More from Products